Identification of immunotherapy and radioimmunotherapy targets on desmoplastic small round cell tumors
Frontiers in Oncology · 05.04.2023 · 13
DOI: 10.3389/fonc.2023.1104693 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 05.04.2023. Verfasst von Madelyn Espinosa-Cotton und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, United States. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
Development of successful antibody-based immunotherapeutic and radioimmunotherapeutic strategies rely on the identification of cell surface tumor-associated antigens (TAA) with restricted expression on normal tissues. Desmoplastic small round cell tumor (DSRCT) is a rare and generally neglected malignancy that primarily affects adolescent and young adult males. New therapies capable of treating disseminated disease are needed for DSRCT, which is often widespread at diagnosis.
Methods
We used immunohistochemistry (IHC) on fresh frozen surgical specimens and patient-derived xenograft (PDX) tumors and flow cytometry on DSRCT cell lines to evaluate expression of TAAs in these tumors. In vitro cytotoxicity assays were used to evaluate the efficacy of T cell-engaging bispecific antibodies (T-BsAbs) directed at these targets. In vivo , we used an intraperitoneal xenograft mouse model of DSRCT to test T-BsAbs against several TAAs.
Results
In DSRCT specimens we found widespread expression of B7-H3, EGFR, GD2, HER2, mesothelin, and polysialic acid, clinical targets for which specific antibody therapeutics are available. The expression of B7-H3, EGFR, HER2, and mesothelin was confirmed on the cell surface of DSRCT cell lines. In vitro cytotoxicity assays confirmed the efficacy of T cell-engaging bispecific antibodies (T-BsAbs) directed at these targets against DSRCT cells. Remarkably, a HER2xCD3 T-BsAb was capable of completely shrinking established tumors in an intraperitoneal mouse model of DSRCT.
Conclusions
We propose that these TAAs should be further investigated in preclinical models as targets for immunotherapy and radioimmunotherapy with the hope of providing a rationale to extend these therapies to patients with advanced DSRCT.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
- Arms Wide Open Childhood Cancer Foundation
Zitieren
APA
Espinosa-Cotton, M., Guo, H. F., Tickoo, S. K., & Cheung, N. V. (2023). Identification of immunotherapy and radioimmunotherapy targets on desmoplastic small round cell tumors. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1104693
Vancouver
Espinosa-Cotton M, Guo HF, Tickoo SK, Cheung NV. Identification of immunotherapy and radioimmunotherapy targets on desmoplastic small round cell tumors. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1104693
BibTeX
@article{EspinosaCotton2023,
author = {Espinosa-Cotton, Madelyn and Guo, Hong-Fen and Tickoo, Satish K and Cheung, Nai-Kong V},
title = {Identification of immunotherapy and radioimmunotherapy targets on desmoplastic small round cell tumors},
journal = {Frontiers in Oncology},
year = {2023},
volume = {13},
doi = {10.3389/fonc.2023.1104693}
}
EUVIMED